# Aktis Oncology (AKTS) — Analyst Forecast

AKTS · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/akts/forecast

## Analyst consensus

| Consensus | Buy | Hold | Sell | Analysts |
| --- | --- | --- | --- | --- |
| Buy | 9 | 0 | 0 | 9 |

## Price target

| Low | Average | High | Analysts |
| --- | --- | --- | --- |
| $35.00 | $37.33 | $40.00 | 3 |

Last price $16.01 (as of Oct 16, 2026).

## Recent analyst ratings

| Date | Firm | Action | Rating | Price target |
| --- | --- | --- | --- | --- |
| Oct 2, 2026 | Wedbush | Maintained | Outperform | $35.00 |
| Sep 9, 2026 | Oppenheimer | Initiated Coverage | Outperform | $40.00 |
| Aug 19, 2026 | Wedbush | Initiated Coverage | Outperform | $35.00 |
| Aug 19, 2026 | BMO Capital | Initiated Coverage | Outperform | $37.00 |
| Jul 14, 2026 | JP Morgan | Maintained | Overweight | $33.00 |
| Jun 16, 2026 | Raymond James | Initiated Coverage | Strong Buy | $40.00 |
| Jun 2, 2026 | HC Wainwright & Co. | Maintained | Buy | $35.00 |
| Apr 29, 2026 | William Blair | Initiated Coverage | Outperform | — |
| Mar 31, 2026 | HC Wainwright & Co. | Maintained | Buy | $33.00 |
| Mar 9, 2026 | HC Wainwright & Co. | Initiated Coverage | Buy | $30.00 |
| Feb 3, 2026 | JP Morgan | Initiated Coverage | Overweight | $30.00 |
| Feb 3, 2026 | Leerink Partners | Initiated Coverage | Outperform | $31.00 |

## Frequently Asked Questions

### What is the price target for AKTS stock?

The average 12-month analyst price target for Aktis Oncology (AKTS) is $37.33, with a high estimate of $40.00 and a low of $35.00, across 3 analysts.

### Is AKTS a buy, sell, or hold?

Analysts covering Aktis Oncology currently average a Buy rating: 9 buy, 0 hold and 0 sell, from 9 analysts. Ratings reflect analyst opinion, not investment advice.

### What upside do analysts see for AKTS?

The average price target of $37.33 implies 133.19% upside from the last price of $16.01.

### What is the latest analyst rating on AKTS?

On Oct 2, 2026, Wedbush maintained Aktis Oncology at Outperform with a price target of $35.00.

---

Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).